NLRP3 inhibitors are drugs that target the NLRP3 inflammasome, a key player in inflammation and immune responses.

OncoResponse, a clinical-stage biotech innovator specializing in immunotherapy derived from elite cancer survivors, announced the first dosing in a Phase 1/2 trial of OR502.

There are two IND categories: Commercial and Research (non-commercial).

Opsidio has initiated dosing of the initial participant in a Phase 2a study evaluating OpSCF for the treatment of moderate to severe eczema.

MAO-B inhibitors are drugs that target the MAO-B enzyme, crucial for regulating neurotransmitters like dopamine.

ASC Therapeutics has reported the inaugural administration to a patient in their Phase I/IIa study for their prime drug, ASC618, conducted at Arkansas Children's Hospital.

There are various types of drug applications submitted to the FDA, including Investigational New Drug (IND), New Drug Application (NDA), Abbreviated New Drug Application (ANDA), Over-the-Counter Drugs (OTC), and Biologic License Application (BLA).

Longboard Pharmaceuticals, Inc., a company focused on developing new treatments for neurological conditions, has announced the start of a Phase 1 trial. This randomized, double-blind, placebo-controlled study will assess their drug candidate, LP659, in a Single Ascending Dose (SAD) format.

Factor Xa inhibitors are anticoagulant drugs that inhibit Factor Xa, a key enzyme in blood coagulation.

OliX Pharmaceuticals has disclosed encouraging initial safety outcomes and signs of effectiveness from a Phase 1 study evaluating OLX10212 for treating age-related macular degeneration.

The Prescription Drug User Fee Act (PDUFA) of 1992 allows the FDA to charge fees to applicants submitting drug applications or sponsors of approved prescription drugs.

Arrowhead Pharmaceuticals has submitted an application to begin an early-stage clinical trial, evaluating ARO-DM1 in patients with Myotonic Dystrophy Type 1.